Thermo Fisher, Danaher stand to gain from drugmakers’ onshoring effortsnews2025-10-22T17:11:30+00:00October 22nd, 2025|Endpoints News|
Top drugmakers’ jets have descended on DC more than 120 times this yearnews2025-10-22T14:45:41+00:00October 22nd, 2025|Endpoints News|
Ipsen to buy ImCheck for €350M to get ‘superfamily’ of immunotherapiesnews2025-10-22T10:28:46+00:00October 22nd, 2025|Endpoints News|
Takeda makes major bispecific, ADC pact with Innovent for $1.2B upfrontnews2025-10-22T07:31:10+00:00October 22nd, 2025|Endpoints News|
10x Genomics files patent suits against Illuminanews2025-10-22T02:01:04+00:00October 22nd, 2025|Endpoints News|
Genmab was one of three bidders before inking $8B Merus acquisitionnews2025-10-22T01:54:06+00:00October 22nd, 2025|Endpoints News|
Cuban’s Cost Plus links with White House’s TrumpRx sitenews2025-10-21T18:34:02+00:00October 21st, 2025|Endpoints News|
Regeneron reaches patent deal with Celltrion over Eylea biosimilarnews2025-10-21T18:16:52+00:00October 21st, 2025|Endpoints News|
Updated: Novo Nordisk’s chair to step down; new board to focus on ‘faster decision-making’news2025-10-21T13:19:41+00:00October 21st, 2025|Endpoints News|
#ESMO25: Roche says ctDNA-guided Tecentriq prolonged survival in bladder cancer patientsnews2025-10-20T15:10:59+00:00October 20th, 2025|Endpoints News|
